What Does a Seronegative NMOSD Diagnosis Mean for You?

Yes, you can be diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) even if your blood test is negative for the AQP4-IgG antibody. When a person has clinical symptoms of NMOSD but the antibody is not detected, it is called AQP4-IgG-negative or seronegative NMOSD.

Because a negative blood test means the primary biological marker for the disease is missing, your medical team must rely on much stricter clinical and imaging rules to confirm the diagnosis and ensure another condition is not causing your symptoms ^[1].

Safety Warning: Never delay treatment for an active attack—such as new vision loss, weakness, numbness, trouble walking, or persistent unexplained hiccups/vomiting—just to wait for a blood test. Acute symptom management always takes priority.

The Stricter Rules for a Seronegative Diagnosis

In 2015, an international panel of experts created updated guidelines (the IPND criteria) for diagnosing NMOSD ^[1]. If your AQP4 blood test is negative (or unavailable), a doctor must observe more stringent evidence before confirming NMOSD:

• Involvement of Multiple Areas: You must have at least two different core clinical characteristics. This means symptoms must affect at least two distinct parts of your central nervous system (such as the optic nerves, the spinal cord, or the brainstem) ^[1]. These can happen during a single attack, or across multiple attacks over time.
• Specific Attack Types: At least one of those clinical characteristics must be one of the classic NMOSD hallmarks:
  • Optic neuritis: Inflammation of the optic nerve causing vision loss or eye pain.
  • Acute myelitis with LETM: Spinal cord inflammation featuring a longitudinally extensive transverse myelitis (LETM), which is an MRI lesion spanning three or more vertebral segments ^[1].
  • Area postrema syndrome: Persistent, unexplained hiccups, nausea, and vomiting caused by inflammation in a specific part of the brainstem ^[1].
• Supportive MRI Findings: Your MRI scans must show specific patterns of damage that align with NMOSD. These imaging requirements depend on your symptoms. For instance, if you have acute myelitis, the MRI typically must show the LETM pattern; if you have optic neuritis, the MRI must show specific patterns of nerve involvement ^[1].
• Exclusion of Alternatives: Your doctor must confirm that no other disease better explains your symptoms and MRI results ^[1].

Why Might Your Test Be Negative?

If you have classic NMOSD symptoms but a negative test, it is important to investigate why the test was negative. A “seronegative” result simply means the test did not detect the antibody; it does not automatically mean you do not have NMOSD.

• Testing Method: The most accurate way to test for the AQP4 antibody is using a cell-based assay (CBA) ^[2]. Older testing methods, like ELISA, are less sensitive and may miss the antibody ^[1].
• Timing and Treatment: If your blood was drawn after you received treatments like plasma exchange (PLEX) or certain immunosuppressants, these therapies can temporarily reduce the detectability of antibodies in your blood ^[3][4]. Your neurologist will decide if repeating the test during a future relapse or before starting a new medication is appropriate ^[1].

The MOGAD Alternative Diagnosis

If you are seronegative for NMOSD, your doctor should test your blood for a different antibody called MOG-IgG using a cell-based assay.

In recent years, researchers discovered that a portion of people who were previously thought to have seronegative NMOSD actually test positive for the MOG antibody. In one study of patients who met the criteria for seronegative NMOSD, 42% tested positive for MOG-IgG ^[5]. When a patient tests positive for this antibody and has matching clinical symptoms, they are diagnosed with MOG Antibody Disease (MOGAD) ^[5][6]. While MOGAD shares many symptoms with NMOSD—such as optic neuritis and spinal cord inflammation—it is a distinct disease with different long-term outcomes and treatment approaches ^[6].

Ruling Out Multiple Sclerosis (MS)

When diagnosing seronegative NMOSD, doctors must carefully rule out other diseases, most notably Multiple Sclerosis (MS) ^[7]. Medical teams distinguish MS from NMOSD by looking at the exact shape and location of lesions on your brain and spinal cord MRI, analyzing your spinal fluid, and reviewing your symptom history ^[7].

Distinguishing the two conditions is critical. Some disease-modifying therapies commonly used to treat MS are ineffective for NMOSD and have even been associated with worsening NMOSD attacks ^[8]. However, you should never stop, start, or change any prescribed MS or NMOSD medication without directly consulting your treating specialist.

If you are facing a potential seronegative NMOSD diagnosis, seeking care from a neuroimmunologist or a specialist in rare demyelinating diseases is highly recommended to help you navigate these complex diagnostic steps.

Common Terms (Glossary)

• AQP4-IgG: An antibody that mistakenly attacks the aquaporin-4 protein in the central nervous system, causing most cases of NMOSD.
• Cell-Based Assay (CBA): The highly sensitive, modern laboratory test recommended for detecting AQP4 and MOG antibodies.
• LETM (Longitudinally Extensive Transverse Myelitis): Inflammation causing a continuous lesion across three or more bones (vertebrae) of the spinal cord on an MRI.
• PLEX (Plasma Exchange): A treatment that filters the blood to remove harmful antibodies during an acute attack.